دورية أكاديمية
أعرض في EDS

Mesenchymal stem cell-derived exosome alleviates sepsis- associated acute liver injury by suppressing MALAT1 through microRNA-26a-5p: an innovative immunopharmacological intervention and therapeutic approach for sepsis.

التفاصيل البيبلوغرافية
العنوان: Mesenchymal stem cell-derived exosome alleviates sepsis- associated acute liver injury by suppressing MALAT1 through microRNA-26a-5p: an innovative immunopharmacological intervention and therapeutic approach for sepsis.
المؤلفون: Cai J; Department of Critical Care Medicine and Hematology, The Third Xiangya Hospital, Central South University, Changsha, China., Tang D; Department of General Surgery, The Third Xiangya Hospital, Central South University, Changsha, China., Hao X; Department of Hematology, Xiangya Hospital, Central South University, Changsha, China.; Key Laboratory of Sepsis Translational Medicine of Hunan, Central South University, Changsha, China., Liu E; Department of Hematology, Xiangya Hospital, Central South University, Changsha, China.; Key Laboratory of Sepsis Translational Medicine of Hunan, Central South University, Changsha, China., Li W; Department of Plastic and Aesthetic (Burn) Surgery, The Second Xiangya Hospital of Central South University, Changsha, China., Shi J; Department of Critical Care Medicine and Hematology, The Third Xiangya Hospital, Central South University, Changsha, China.
المصدر: Frontiers in immunology [Front Immunol] 2023 Jun 15; Vol. 14, pp. 1157793. Date of Electronic Publication: 2023 Jun 15 (Print Publication: 2023).
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Lausanne : Frontiers Research Foundation]
مواضيع طبية MeSH: Exosomes*/metabolism , Mesenchymal Stem Cells*/metabolism , MicroRNAs*/genetics , MicroRNAs*/metabolism , RNA, Long Noncoding*/genetics , RNA, Long Noncoding*/metabolism , Sepsis*/complications , Sepsis*/therapy , Sepsis*/genetics, Animals ; Mice ; Liver/metabolism
مستخلص: Background: Sepsis is a syndrome with the disturbed host response to severe infection and is a major health problem worldwide. As the front line of infection defense and drug metabolism, the liver is vulnerable to infection- or drug-induced injury. Acute liver injury (ALI) is thus common in patients with sepsis and is significantly associated with poor prognosis. However, there are still few targeted drugs for the treatment of this syndrome in clinics. Recent studies have reported that mesenchymal stem cells (MSCs) show potential for the treatment of various diseases, while the molecular mechanisms remain incompletely characterized.
Aims and Methods: Herein, we used cecal ligation puncture (CLP) and lipopolysaccharide (LPS) plus D-galactosamine (D-gal) as sepsis-induced ALI models to investigate the roles and mechanisms of mesenchymal stem cells (MSCs) in the treatment of ALI in sepsis.
Results: We found that either MSCs or MSC-derived exosome significantly attenuated ALI and consequent death in sepsis. miR-26a-5p, a microRNA downregulated in septic mice, was replenished by MSC-derived exosome. Replenishment of miR-26a-5p protected against hepatocyte death and liver injury caused by sepsis through targeting Metastasis Associated Lung Adenocarcinoma Transcript 1 (MALAT1), a long non-coding RNA highly presented in hepatocyte and liver under sepsis and inhibiting anti-oxidant system.
Conclusion: Taken together, the results of the current study revealed the beneficial effects of MSC, exosome or miR-26a-5p on ALI, and determined the potential mechanisms of ALI induced by sepsis. MALAT1 would be a novel target for drug development in the treatment of this syndrome.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2023 Cai, Tang, Hao, Liu, Li and Shi.)
References: Science. 2022 May 6;376(6593):609-615. (PMID: 35511979)
Cell Biol Toxicol. 2022 May 13;:. (PMID: 35554780)
Redox Biol. 2022 Aug;54:102377. (PMID: 35763934)
Curr Opin Crit Care. 2013 Apr;19(2):123-7. (PMID: 23448974)
Mol Ther. 2017 Feb 1;25(2):465-479. (PMID: 28089078)
Crit Care. 2012 Oct 30;16(5):235. (PMID: 23134597)
J Immunol Methods. 1979;27(2):159-73. (PMID: 458170)
Nat Rev Nephrol. 2018 Aug;14(8):493-507. (PMID: 29895977)
Lancet. 2020 Jan 18;395(10219):200-211. (PMID: 31954465)
Cancer Res. 2009 Jul 1;69(13):5331-9. (PMID: 19509230)
Am J Transl Res. 2016 Dec 15;8(12):5685-5695. (PMID: 28078039)
Stem Cells Transl Med. 2017 Apr;6(4):1262-1272. (PMID: 28213967)
Front Immunol. 2018 Jun 26;9:1460. (PMID: 29997622)
Eur Urol. 2016 Aug;70(2):312-22. (PMID: 26806656)
Nat Rev Dis Primers. 2016 Jun 02;2:16037. (PMID: 27250996)
Mol Cancer. 2010 Sep 03;9:232. (PMID: 20815877)
Biochem Biophys Res Commun. 2018 Jan 15;495(3):2111-2117. (PMID: 29258822)
Nat Rev Rheumatol. 2013 Feb;9(2):76-8. (PMID: 23321608)
Biochem Biophys Res Commun. 2019 Feb 5;509(2):359-366. (PMID: 30591217)
Trends Mol Med. 2014 Aug;20(8):460-9. (PMID: 25027972)
Semin Cancer Biol. 2017 Jun;44:132-140. (PMID: 28344166)
Cytotherapy. 2016 Dec;18(12):1548-1559. (PMID: 27592404)
Annu Rev Immunol. 2018 Apr 26;36:247-277. (PMID: 29328785)
Crit Care Med. 2007 Apr;35(4):1099-104. (PMID: 17334250)
Hepatology. 2006 Feb;43(2 Suppl 1):S54-62. (PMID: 16447271)
Eur Rev Med Pharmacol Sci. 2017 Jan;21(2):302-309. (PMID: 28165557)
Inflamm Regen. 2016 Nov 17;36:26. (PMID: 29259699)
Crit Care Med. 2014 Mar;42(3):625-31. (PMID: 24201173)
Cell Stem Cell. 2018 Jun 01;22(6):824-833. (PMID: 29859173)
Mol Ther Nucleic Acids. 2020 Sep 4;21:51-74. (PMID: 32506014)
فهرسة مساهمة: Keywords: MALAT1; exosome; immune regulation; immunopharmacological interventions; mesenchymal stem cells; miR-26a-5p; sepsis
المشرفين على المادة: 0 (MicroRNAs)
0 (RNA, Long Noncoding)
0 (Malat1 long non-coding RNA, mouse)
0 (Mirn26 microRNA, mouse)
تواريخ الأحداث: Date Created: 20230703 Date Completed: 20230710 Latest Revision: 20230710
رمز التحديث: 20240514
مُعرف محوري في PubMed: PMC10310917
DOI: 10.3389/fimmu.2023.1157793
PMID: 37398640
قاعدة البيانات: MEDLINE
الوصف
تدمد:1664-3224
DOI:10.3389/fimmu.2023.1157793